| Related party transactions |
| 25. | Related party transactions |
The table below sets forth the major related parties and
their relationships with the Company as of March 31, 2024, 2025 and 2026:
| Name of related parties | | Relationship with the Company | | Nanjing Animal Pharmaceutical | | An equity investee of the Company until December, 2022 | | Wuhan Chunzhijin | | An equity investee of the Company | | Weishi Network | | An equity investee of the Company | | Beijing Petdog | | An available-for-sale investee that the Company has significant influence | | Shanghai Chelin Information Technology Center (limited partnership) (“Shanghai Chalin Information”) | | A company with a common director of the Company | | MERCHANT TYCOON LIMITED | | A shareholder of the Company | | SUPERB ORIGIN INTERNATIONAL LIMITED | | A shareholder of the Company | | Yingzhi (Lisa) Tang | | Senior management of the Company | | Yan Jiang | | Senior management of the Company |
Details of related party transactions are as follows:
| | |
Year Ended March 31,
2024 | | |
Year Ended March 31,
2025 | | |
Year Ended March 31,
2026 | |
| | |
RMB | | |
RMB | | |
RMB | |
| | |
| | |
| | |
| |
| Purchase of merchandise | |
| | |
| | |
| |
| | |
| | | |
| | | |
| | |
| Nanjing Animal Pharmaceutical | |
| 3,891 | | |
| - | | |
| - | |
| | |
| 3,891 | | |
| - | | |
| - | |
| | |
Year Ended March 31,
2024 | | |
Year Ended March 31,
2025 | | |
Year Ended March 31,
2026 | |
| | |
RMB | | |
RMB | | |
RMB | |
| | |
| | |
| | |
| |
| Loans granted to related parties | |
| | |
| | |
| |
| | |
| | | |
| | | |
| | |
| Wuhan Chunzhijin (a) | |
| 4,761 | | |
| 1,989 | | |
| 680 | |
| | |
| 4,761 | | |
| 1,989 | | |
| 680 | |
| (a) | The Company entered into a loan agreement with Wuhan Chunzhijin
to provide Wuhan Chunzhijin with an interest-free loan of up to RMB10 million, which will be repaid on demand. In March 2023, the Company
converted RMB3.4 million loan to Wuhan Chunzhijin into equity interest. (Detail refer to Note 10). |
| | |
Year Ended March 31,
2024 | | |
Year Ended March 31,
2025 | | |
Year Ended March 31,
2026 | |
| | |
RMB | | |
RMB | | |
RMB | |
| Advances provided to related parties | |
| | |
| | |
| |
| | |
| | | |
| | | |
| | |
| SUPERB ORIGIN INTERNATIONAL LIMITED (a) | |
| - | | |
| 14,433 | | |
| - | |
| Nanjing Animal Pharmaceutical (b) | |
| 5,413 | | |
| - | | |
| - | |
| Weishi Network (c) | |
| - | | |
| - | | |
| 980 | |
| | |
| 5,413 | | |
| 14,433 | | |
| 980 | |
| (a) | In January 2023 and June 2024, the Company made an advance
payment of RMB 5.5 million and RMB 14.4 million, respectively, to SUPERB ORIGIN INTERNATIONAL LIMITED for the purchase of goods. As of
March 31, 2025 and 2026, the balance of the advance payment was RMB18.7 million and RMB 17.1 million respectively, both of which are
recorded as Prepayments to related parties. |
| (b) | During the years ended March 31, 2024, 2025 and 2026, the
Company made advance payments totaling RMB 5.4 million, Nil and Nil, respectively, to Nanjing Animal Pharmaceutical for the purchase
of goods. |
| (c) | During the years ended March 31, 2026, the Company made advance
payments totaling RMB0.98 million to Weishi Network for the purchase of goods. |
Details of related party balances are as follows:
Amounts due from related parties
| | |
As of
March 31, | | |
As of
March 31, | | |
As of
March 31, | |
| | |
2024 | | |
2025 | | |
2026 | |
| | |
RMB | | |
RMB | | |
RMB | |
| | |
| | |
| | |
| |
| Prepayments to related parties | |
| | |
| | |
| |
| | |
| | | |
| | | |
| | |
| SUPERB ORIGIN INTERNATIONAL LIMITED | |
| 4,065 | | |
| 18,670 | | |
| 17,077 | |
| Weishi Network | |
| 1,401 | | |
| 1,134 | | |
| 1,362 | |
| | |
| 5,466 | | |
| 19,804 | | |
| 18,439 | |
| | |
| | | |
| | | |
| | |
| Other receivables from related parties | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | |
| Wuhan Chunzhijin | |
| 5,658 | | |
| 4,935 | | |
| 5,394 | |
| | |
| | | |
| | | |
| | |
| Loans to related parties | |
| | | |
| | | |
| | |
| Yan Jiang | |
| 211 | | |
| - | | |
| - | |
| Shanghai Guangcheng Information | |
| 27 | | |
| - | | |
| - | |
| | |
| 238 | | |
| - | | |
| - | |
Amounts due to related parties
| | |
As of
March 31, | | |
As of
March 31, | | |
As of
March 31, | |
| | |
2024 | | |
2025 | | |
2026 | |
| | |
RMB | | |
RMB | | |
RMB | |
| | |
| | |
| | |
| |
| Trade payables to related parties | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | |
| Nanjing Animal Pharmaceutical | |
| 471 | | |
| - | | |
| - | |
|